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re BNP Changes
uring Hospitalization
or Heart Failure a Reliable
urrogate for Predicting the
ffects of Therapies on
ost-Discharge Mortality?*
ihai Gheorghiade, MD,† Peter S. Pang, MD‡
hicago, Illinois
ince the discovery of B-type natriuretic peptide (BNP) as
cardiac hormone in 1991, it has been well studied as a
iagnostic and prognostic marker in heart failure (HF).
NP has also been investigated for its role in cost-
ffectiveness, as a guide to therapy, as a therapy itself, as
nclusion criteria for clinical research, and as an end point/
urrogate marker in clinical trials (1–6). BNP is secreted
rimarily by cardiac myocytes in response to stretch, due
o pressure or volume overload (7). BNP acts as a counter-
egulatory hormone, counterbalancing the negative ef-
ects of the renin-angiotensin-aldosterone system and
See page 2343
ympathetic nervous system (SNS) by promoting vasodila-
ion, diuresis, and natriuresis (1,8). Although BNP-guided
herapy has shown some promise (9), reductions in BNP
lone, however, are not acceptable for regulatory approval of
ovel therapies and remain an area of debate (10).
In this issue of the Journal, Cohen-Solal et al. (11) report
heir findings from a retrospective analysis of the SURVIVE
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ioPharma.Survival in Patients with Acute Heart Failure in Need of
ntravenous Inotropic Support) trial, of patients who were
andomized to levosimendan or dobutamine. In this highly
elect group of patients, the authors examined measured
NP at days 1, 3, and 5 and correlated changes over time
ith mortality. Patients with reductions in BNP 30% or
n absolute reduction to 800 pg/ml over the first 5 days
ad better survival at 31 and 180 days. Changes in BNP
ere observed in the context of a short-term intervention
uring hospitalization with either levosimendan or do-
utamine when added to standard therapy that included
iuretics, angiotensin-converting enzyme inhibitors or
ngiotensin receptor blockers, aldosterone antagonists,
nd beta-blockers. The lower BNP levels in this study
ay reflect the hemodynamic changes that were seen
ith levosimendan in the LIDO (Levosimendan Infusion
ersus Dobutamine) trial (12).
The conclusions of this study should be interpreted with
aution. Several well-validated prognostic variables, includ-
ng blood urea nitrogen, serum sodium, heart rate, and age,
ere not included in the model. Although SBP at baseline
s accounted for, there was no assessment of whether SBP at
ay 5 or changes in SBP would have been as or more
redictive compared to changes in BNP. It is interesting
hat patients with higher mortality had a lower BNP at
aseline. This contradicts available data, which suggest that
rognosis is associated with higher BNP levels (5). How-
ver, it is possible that changes in BNP are more powerful
redictors than baseline value.
The authors’ conclusion is appealing: reduction of
NP levels over 5 days as part of an in-hospital treatment
lgorithm will facilitate optimization of therapy, resulting
n better post-discharge outcomes. Although the authors
learly state that this requires confirmatory testing, such
hypothesis has important implications for clinical prac-
ice and clinical trials in acute heart failure syndromes
AHFS) because the number of patients hospitalized
ith HF continues to grow. AHFS is associated with a
ost exceeding $17 billion per year with over 3 million
ospital diagnoses each year and more expected as the
opulation ages. Although most patients appear to im-
rove during hospitalization with available therapies,
heir post-discharge rehospitalization and mortality rates
ithin 60 days can be as high as 30% to 40% (13–15).
ttempts to improve clinical outcomes with novel ther-
pies have largely failed in terms of efficacy and/or safety
6,16 –20). Given the difficulties in conducting large-
cale mortality trials in AHFS, an accepted surrogate
arker for outcomes, such as BNP, may provide objective
roof of the efficacy of interventions during hospitaliza-
ion to improve long-term outcomes.
However, prior data from the levosimendan clinical
evelopment program suggest a different conclusion from
hat suggested by Cohen-Solal et al. (11): decreases in BNP
ay be associated with no benefit or even worse outcomes.
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BNP Changes and Post-Discharge Mortality June 23, 2009:2349–52he SURVIVE trial examined 1,327 patients admitted with
orsening HF and low ejection fraction (20). All-cause
ortality at 180 days occurred in 26% of the levosimendan
reatment arm versus 28% in the dobutamine arm. Al-
hough levosimendan-treated patients had a substantial
eduction in BNP at 24 h through 5 days when compared to
obutamine, the survival curves demonstrated no statisti-
ally significant difference (Figs. 1 and 2).
The REVIVE (Randomized Evaluation of Intravenous
evosimendan Efficacy) trials were 2 sequential trials total-
ng 700 patients, with similar inclusion/exclusion criteria,
ame duration of infusion, and measurement of BNP at 24 h
nd at 5 days, similar to the SURVIVE trial (21). Unlike
URVIVE, the REVIVE trials tested levosimendan against
lacebo. Despite a significant reduction in BNP, use of
evosimendan was associated with more adverse events such
s ventricular tachycardia (17% vs. 25%), atrial fibrillation
2% vs. 9%), and hypotension (36% vs. 50%). In addition, a
rend toward increased mortality was seen during the first 5
ays of hospitalization (21). It should be pointed out that
he analysis by Cohen-Solal et al. (11) excluded the 69
atients (5.2%) who died within the first 5 days.
Overall, in both the SURVIVE and REVIVE trials,
eductions in BNP over 5 days did not translate into
mproved outcomes. This may be explained by adverse
ffects of levosimendan, despite reductions in BNP. For
xample, a significant reduction in SBP and an increase in
eart rate was seen with levosimendan, which may have
educed coronary perfusion. The importance of coronary
erfusion, particularly in patients with coronary artery dis-
ase and AHFS, has been recently recognized (22,23). It is
lso important to distinguish between prognostic markers
nd pathophysiologic targets; “improving” a marker may not
lter the underlying pathophysiology nor, therefore, the
utcomes.
Figure 1
Mean Change From Baseline in
B-Type Natriuretic Peptide Levels
at 1, 3, and 5 Days by Treatment Group
There was significantly greater mean change from baseline in plasma B-type
natriuretic peptide levels in the levosimendan group at 1, 3, and 5 days after
initiation of study drug infusion. p  0.001 at all 3 time points. Reproduced,
with permission, from Mebazaa et al. (20). Copyright 2007 American Medical
Association. All rights reserved.EThe CAST (Cardiac Arrhythmia Suppression Trial),
tudying post-myocardial infarction patients with left ven-
ricular dysfunction, provides a historical analogy (24,25).
lthough post-myocardial infarction ventricular premature
eats (VPBs) negatively predict prognosis, active suppres-
ion of VPBs by encainide, flecainide, and moricizine in
AST I and II translated into worse outcomes (24,25). It is
nteresting that during the pre-randomization phase, sup-
ression of VPBs in CAST by these agents was associated
ith an improvement in long-term outcomes, but only if
hose therapies were discontinued. The Cohen-Solal et al.
11) findings support the concept that short-term improve-
ent of a prognostic marker, in this case BNP, identifies a
opulation at lower risk. However, this should not be
nterpreted as a positive response to a specific therapy, in
his case levosimendan.
In acute or chronic HF clinical trials, targeting hemo-
ynamics, body weight, serum sodium, neurohormones,
r renal function— known predictors of prognosis— have
ot always been associated with improved clinical out-
omes (6,18,26 –29) (Table 1). In VMAC (Vasodilation
n the Management of Acute Congestive Heart Failure),
espite hemodynamic improvement in pulmonary capil-
ary wedge pressure (PCWP), no mortality benefit was
een (6). Furthermore, post-approval concerns arose re-
arding an increase in mortality (30). The improvement
n renal function in response to milrinone in OPTIME-
HF (Outcomes of a Prospective Trial of Intravenous
ilrinone for Exacerbations of Chronic Heart Failure)
16,28) was not associated with improved clinical out-
omes. In fact, post-discharge mortality was increased in
atients with coronary artery disease (23).
The short-term interventions in those examples may
inder extrapolation to long-term outcomes. However, in
Figure 2
Effect of Dobutamine and Levosimendan
Treatment on All-Cause Mortality During 180
Days Following the Start of Study Drug Infusion
Reproduced, with permission, from Mebazaa et al. (20).
Copyright 2007 American Medical Association. All rights reserved.VEREST (Efficacy of Vasopressin Antagonism in Heart
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June 23, 2009:2349–52 BNP Changes and Post-Discharge Mortalityailure Outcome Study with Tolvaptan), rapid and sus-
ained decreases in body weight throughout hospitalization
nd after discharge without any major side effects did not
esult in either short- or long-term rehospitalization or
ortality benefits (18,31) In retrospect, in the same trial,
orrection of hyponatremia, a known negative prognostic
arker, was not associated with a mortality benefit (32,33).
n the MOXSE (Moxonidine Safety and Efficacy) and
OXCON (Moxonidine Congestive HF) studies, signifi-
ant reductions in norepinephrine, in addition to objective
everse remodeling, did not affect long-term outcomes; in
act, treated patients had an increase in clinical events
27,34). The FIRST (Flolan International Randomized
urvival Trial) demonstrated effective decreases in PCWP
ith epoprostenol (29). Despite a reduction in PCWP
eing predictive for survival overall, reductions in PCWP by
poprostenol were not associated with improved outcomes
30). Interventions to improve ventricular dyssynchrony in
F provide a welcome contrast. Prolonged QRS duration,
marker of ventricular dyssynchrony and a negative prog-
ostic marker when present despite maximal medical ther-
py, was successfully targeted by chronic resynchronization
herapy resulting in improved long-term outcomes (35,36).
To date, attempts to improve outcomes by targeting HF
rognostic markers with pharmacological therapies unknown
o affect outcomes have been largely futile. Markers are not
ediators, and a marker with one therapy may not be a marker
ith another therapy with a different mechanism of action.
espite an appropriate choice of marker or pathophysiologic
arget, untoward drug effects may obfuscate the benefits.
In summary, this retrospective analysis from the SUR-
IVE trial suggests that short-term reductions in BNP
uring hospitalizations for HF is associated with an
ncrease in survival post-discharge. However, the hypoth-
sis generated by the authors that reductions in BNP are
reliable surrogate for post-discharge mortality as a
esult of early therapeutic optimization is not supported
elected Prognostic Markers as Targets in HF Clinical Trials
Table 1 Selected Prognostic Markers as Targets in HF Clinical
Prognostic Marker/Predictor Inte
Hemodynamics Yes Epoprostenol (FIR
Nesiritide (VMAC)
Neurohormones Yes (BNP) Levosimendan (RE
Yes (norepinephrine) Moxonidine (MOX
Yes (endothelin) Tezosentan (VERIT
Yes (TNF) Etanercept (RECO
Renal function Yes (BUN, Cr, eGFR) Milrinone (OPTIME
Serum sodium Yes Tolvaptan (EVERE
Body weight Yes Tolvaptan (EVERE
QRS duration Yes CRT (CARE-HF)‡
uration of intervention (how long therapy was given): short indicates within hospitalization onl
rognostic marker occurred): short indicates 7 days; long indicates 7 days. *Retrospective tre
Chronic HF trials.
BNP  B-type natriuretic peptide; BUN  blood urea nitrogen; Cr  creatinine; CRT  chronic r
ecrosis factor.y either the SURVIVE or the REVIVE trials; a signif-
ncant decrease in BNP with levosimendan was not asso-
iated with improved outcomes. In fact, there were more
dverse events in patients treated with levosimendan and
trend toward worse outcomes. In contrast to the
onclusions drawn by Cohen-Solal et al. (11), their data
uggest that the overall clinical effect of a given drug
annot be captured by changes of a prognostic marker,
ince the drug may “improve” the marker by different
echanisms and/or have other potential deleterious ef-
ects. In aggregate, the available data suggest that there
re no surrogate end points in HF for clinical events such
s mortality or rehospitalizations. Although intuitively
ppealing, for day-to-day clinical practice, extrapolating
hanges in prognostic markers to outcomes should be
one with caution unless therapies known to improve
utcomes and/or have a proven safety profile are used to
chieve those goals. Given the current absence of such
vidence-based therapies in AHFS, a significant thera-
eutic need exists. Future clinical trials should also
efrain from using surrogates as end points; either dem-
nstrate clinical improvement with safety or improve
linical outcomes, irrespective of changes in markers.
evertheless, the paper by Cohen-Solal et al. (11) raises
n important hypothesis that remains to be tested: in
atients hospitalized with severe heart failure, a signifi-
ant decrease in BNP over a few days irrespective of any
pecific therapy is a better predictor of prognosis than the
aseline BNP measurement.
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Duration of Intervention/
Time of Assessment Outcomes: Mortality
Long/short No benefit
Short/short No benefit*
SURVIVE) Short/long No benefit†
OXSE) Long/long Worse
Short/short No benefit
ENAISSANCE)‡ Long/long No benefit
Short/long No benefit
Long/long No benefit
Long/long No benefit
Long/long Positive
indicates continued post-discharge or as outpatient. Time of assessment (when assessment of
rds increased mortality. †The REVIVE trial showed a trend toward an increase in early mortality.
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